[{"NetIncomeLossConverted_1_Q1_USD":38100000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":133200000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":200000.0,"EarningsPerShareDiluted_1_Q1_USD":0.28,"StockholdersEquity_0_Q1_USD":5558000000.0,"RevenuesConverted_1_Q1_USD":1010000000.0,"Assets_0_Q1_USD":11324800000.0,"CommonStockSharesConverted_0_Q1_shares":133500000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":134600000.0,"EarningsPerShareBasic_1_Q1_USD":0.29,"Ticker":"PRGO","CIK":"1585364","name":"PERRIGO CO PLC","OfficialName":"Perrigo Company plc Ordinary Shares","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"4754722726.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20210512"}]